Abstract
New oncology approvals from 2017 to 2018 were mostly for additional indications, with many agents moved up to first-line therapy. Patrick J. Kiel, PharmD, BCPS, BCOP, detailed their implications for advanced practice.
2017-2018 Drug Approvals in Solid Tumors
April 22, 2019
Volume 10, Number 3 (Apr 2019)
https://doi.org/10.6004/jadpro.2019.10.3.3
